Rosemont Pharmaceuticals, currently owned by CBPE, has been placed into a sales process and is expected to fetch around £200m (€251.7m).

CBPE acquired the liquid medicine manufacturer in September 2006, backing its £93m buyout from Nasdaq-listed Savient Pharmaceuticals. 

Rothschild has been appointed to oversee the sale. According to reports, the company has already attracted private equity and larger pharmaceutical companies. 

Leeds-based Rosemont manufactures over 150 liquid medicines targeted at people who have difficulties swallowing solid medication. Patients who struggle with solid medicines often crush their tablets,but this can lead to complications and potential overdose. Tablets are also designed to be broken down in the body and absorbed at a certain rate. When crushed, the drugs are absorbed faster. Liquid medicines avoid this risk.